Actuate Therapeutics (ACTU) Operating Income (2023 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Operating Income of -$4.7 million for Q4 2025, up 28.52% year-over-year from -$3.6 million in Q4 2024, and up 14.32% quarter-over-quarter from -$5.5 million in Q3 2025.
Actuate Therapeutics (ACTU) Operating Income (2023 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Operating Income for 3 consecutive years, with -$4.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Income rose 28.52% year-over-year to -$4.7 million; the TTM figure through Dec 2025 stood at -$22.5 million (up 10.59% YoY), while the FY2025 annual figure was -$22.5 million, up 10.59% from the prior year.
- Operating Income advanced to -$4.7 million in Q4 2025 per ACTU's latest filing, from -$5.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$4.7 million in Q4 2025 and bottomed at -$7.8 million in Q1 2024.
- Historically, Operating Income has averaged -$6.1 million across 3 years, with a median of -$6.0 million in 2025.
- On a YoY basis, Operating Income climbed as much as 28.52% in 2025 and fell as far as 9.81% in 2025.
- Actuate Therapeutics' Operating Income stood at -$7.6 million in 2023, then climbed by 13.87% to -$6.6 million in 2024, then rose by 28.52% to -$4.7 million in 2025.
- Business Quant data shows ACTU's Operating Income at -$4.7 million in Q4 2025, -$5.5 million in Q3 2025, and -$6.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 133.12 Mn |
| 10 | Actuate Therapeutics | 28.52 Mn | 28.52 Mn | - | -4.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.69 Mn |
| Sep 30, 2025 | -5.47 Mn |
| Jun 30, 2025 | -5.97 Mn |
| Mar 31, 2025 | -6.37 Mn |
| Dec 31, 2024 | -6.56 Mn |
| Sep 30, 2024 | -5.39 Mn |
| Jun 30, 2024 | -5.44 Mn |
| Mar 31, 2024 | -7.77 Mn |
| Dec 31, 2023 | -7.62 Mn |
| Sep 30, 2023 | -6.48 Mn |
| Jun 30, 2023 | -5.58 Mn |